Navigation Links
Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer
Date:9/10/2009

ents with a history of cardiovascular disease, or if the results of cardiac monitoring indicate possible cardiac injury, the benefit of therapy must be weighed against the risk of myocardial injury
  • In the randomized multiple myeloma study, 25 patients (8%) in the VELCADE for Injection arm and 42 patients (13%) in the VELCADE plus DOXIL arm experienced left ventricular ejection fraction decrease (defined as absolute decrease greater than or equal to 15% over baseline or a greater than or equal to 5% decrease below institutional lower limit of normal)
  • Myelosuppression may occur; frequently monitor complete blood count (including platelet count), at least prior to each dose of DOXIL
    • In patients with recurrent ovarian cancer or AIDS-related Kaposi's sarcoma, hematologic toxicity (based on platelet count or absolute neutrophil count) may require dose reduction or delay in administration of DOXIL
    • In patients with multiple myeloma, hematologic toxicity (based on platelet count, absolute neutrophil count, hemoglobin level, or neutropenia with fever) may require dose reduction, delay in administration, or suspension of DOXIL and/or VELCADE
    • Persistent severe myelosuppression may result in superinfection, neutropenic fever, or hemorrhage
    • Sepsis occurring during neutropenia has resulted in discontinuation of treatment and in rare cases of death
  • DOXIL may potentiate the toxicity of other anticancer therapies, especially hematologic toxicities, when used in combination with other therapies that suppress bone marrow
  • Hand-foot syndrome (HFS) may occur during therapy with DOXIL
    • Based on HFS toxicity grade, dose reduction, or delay in administration, or discontinuation of DOXIL may be required
    • HFS was generally observed after 2 to 3 cycles of treatment, but may occu
      '/>"/>

    SOURCE Centocor Ortho Biotech Products, L.P.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
    2. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
    3. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
    4. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
    5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
    6. GeneNews provides Centocor access to its osteoarthritis program
    7. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
    8. Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
    9. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
    10. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
    11. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
  • Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/1/2014)... , Oct. 1, 2014 Pfanstiehl has ... (USP/NF, EP), manufactured in the USA ... has long been recognized for playing a key ... growing body of evidence that media supplementation with ... of protein glycosylation," according to Dr. Christopher ...
    (Date:10/1/2014)... New applications of structures and materials that ... nature over millennia are featured in a special ... in biophotonics in the October issue of the ... by SPIE, the international society for optics and photonics, ... articles are accessible via open access. , “Biomimetic and ...
    (Date:10/1/2014)... 30, 2014 This report analyzes ... US$ Million by the following Product Segments: ... Specific end-use segments also analyzed are Pharmaceuticals ... The report provides separate comprehensive analytics for ... East, and Latin America. Annual estimates and ...
    (Date:9/30/2014)... Mass. Using a bio-mimicking analog of one ... grass, an international research team led by Alejandro ... taken a major step in developing long-sought polymer ... electricity for use in electronic devices. , ... Amherst and others at Stanford University and Dresden ...
    Breaking Biology Technology:Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3
    ... Inc. (NASDAQ: SQNM ), a life sciences ... acceptance for publication of the manuscript, "Clinical Validation of ... Choroidal Neovascular Age-related Macular Degeneration." The article will appear ... The study, conducted by the company,s wholly-owned subsidiary, Sequenom ...
    ... National Institute of Standards and Technology (NIST) colored lots ... eggs a bit smallin fact, too small to see ... practical use, suggesting strategies for making future low-power computer ... paper,* NIST researchers used electron-beam lithography to make thousands ...
    ... PARK, N.C., April 27, 2011 Talecris Biotherapeutics Holdings ... its financial results for the three months ended March ... U.S. Securities and Exchange Commission (SEC). First ... 6.7% to $406.7 million from $381.0 million in the ...
    Cached Biology Technology:Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 2Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 3Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 4Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 5Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 6Good eggs: NIST nanomagnets offer food for thought about computer memories 2Talecris Biotherapeutics Announces First Quarter 2011 Results 2Talecris Biotherapeutics Announces First Quarter 2011 Results 3Talecris Biotherapeutics Announces First Quarter 2011 Results 4Talecris Biotherapeutics Announces First Quarter 2011 Results 5Talecris Biotherapeutics Announces First Quarter 2011 Results 6Talecris Biotherapeutics Announces First Quarter 2011 Results 7Talecris Biotherapeutics Announces First Quarter 2011 Results 8Talecris Biotherapeutics Announces First Quarter 2011 Results 9Talecris Biotherapeutics Announces First Quarter 2011 Results 10Talecris Biotherapeutics Announces First Quarter 2011 Results 11Talecris Biotherapeutics Announces First Quarter 2011 Results 12Talecris Biotherapeutics Announces First Quarter 2011 Results 13Talecris Biotherapeutics Announces First Quarter 2011 Results 14Talecris Biotherapeutics Announces First Quarter 2011 Results 15Talecris Biotherapeutics Announces First Quarter 2011 Results 16
    (Date:9/30/2014)... drinking water may increase the risk of stillbirth ... led by a Boston University School of Public ... journal Environmental Health , compared 1,091 PCE-exposed ... in Cape Cod, Ma., where water was contaminated ... by the installation of vinyl-lined asbestos cement pipes. ...
    (Date:9/30/2014)... This news release is available in German . ... caviar, are among the most expensive foods in the world. ... to find them. But the distinctive smell of truffles is ... and French scientists under the direction of the Goethe University ... largely produced by soil bacteria which are trapped inside truffle ...
    (Date:9/30/2014)... Munich report that a new class of chemical ... drugs. They have also pinpointed the relevant target ... agents. , Researchers led by LMU,s Professor ... Technische Universitt Mnchen have identified a class of ... the fight against malignant tumors. The compound is ...
    Breaking Biology News(10 mins):Contaminated water linked to pregnancy complications, BU study finds 2On the trail of the truffle flavor 2Cancer therapy: Driving cancer cells to suicide 2
    ... Though promiscuity may be risky behavior for humans, it's ... surfeits with multiple drones produce more disease-resistant colonies than ... published in the Jan. 7 issue of the Proceedings ... of queen honeybees has long perplexed apiculturists, especially since ...
    ... from The Wistar Institute in Philadelphia and The Vienna ... in normal repression of the p53 protein, perhaps the ... in humans. , The new molecular pathway described ... intervening in the progression of many types of cancer. ...
    ... influenza viruses found in birds with those of the avian ... key genetic changes required for pandemic strains of bird flu. ... of the journal Nature, illustrates the genetic changes required for ... the receptors that are the gateway to human cells. ...
    Cached Biology News:Queen bee promiscuity boosts hive health 2Novel regulatory mechanism identified for key tumor suppressor p53 2Novel regulatory mechanism identified for key tumor suppressor p53 3Scientists find mutations that let bird flu adapt to humans 2
    Recombinant Mouse Wnt-3a...
    ... at least 20 structurally and functionally related ... superfamily. BMPs were originally identified as protein ... are also involved in embryogenesis and morphogenesis ... the growth, differentiation, chemotaxis and apoptosis of ...
    RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
    RABBIT ANTI HUMAN CHYMOTRYPSIN...
    Biology Products: